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Although cancer mortality is declining in some 
European Union countries, lifestyle factors and the 
ageing population mean that cancer incidence will 
continue to rise1. Cancer survival gains will result from 
improved curative treatment2, and among those cancer 
patients who are cured, it has been estimated that 49% 
are cured by surgery, 40% by radiotherapy alone or com-
bined with other modalities, and 11% by chemotherapy 
alone or combined with other modalities3. Radiotherapy 
is also a highly effective treatment for palliation and 
symptom control in patients with advanced-stage or 
recurrent cancer4.
Radiotherapy is a very cost-effective component of 
cancer care. The estimated total cost of radiotherapy 
in the UK was only 5% of the estimated total cost of 
cancer care, which is representative of other developed 
countries5,6. Significant technical advances, such as 
image-guided radiotherapy, intensity-modulated radio-
therapy, stereotactic radiotherapy, and proton therapy 
have enabled, when compared with conventional radio-
therapy, the application of higher radiation doses and 
more precise cancer targeting with considerably lower 
doses to non-malignant surrounding tissues. These 
advances have improved patient outcomes7,8. Moreover, 
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Abstract | In countries with the best cancer outcomes, approximately 60% of patients receive 
radiotherapy as part of their treatment, which is one of the most cost-effective cancer 
treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a 
single modality or combined with other treatments. Radiotherapy can provide enormous 
benefit to patients with cancer. In the past decade, significant technical advances, such as 
image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy,  
and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with 
significantly lower doses to normal surrounding tissues. However, apart from the combination 
of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in 
identifying and defining optimal targeted therapy and radiotherapy combinations to improve 
the efficacy of cancer treatment. The National Cancer Research Institute Clinical and 
Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group 
with representatives from academia, industry, patient groups and regulatory bodies to address 
this lack of progress and to publish recommendations for future clinical research. Herein, we 
highlight the Working Group’s consensus recommendations to increase the number of novel 
drugs being successfully registered in combination with radiotherapy to improve clinical 
outcomes for patients with cancer.
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there is clear (Level 1) evidence that drug-radiotherapy 
combinations improve overall survival9. Apart from 
the combination of traditional cytotoxic chemotherapy 
with radiotherapy, however, limited progress has been 
made in using potential synergies between targeted sys-
temic therapies and radiotherapy. Specifically, very few 
new drug–radiotherapy combinations are registered10,11. 
There is an unmet need for intelligent and rational 
approaches to drug–radiotherapy combinations on 
the basis of our molecular understanding of radio-
biology and increased ability to develop agents that 
can be combined with radiotherapy in preclinical 
 models. To define the most rational clinical approaches, 
the National Cancer Research Institute Clinical and 
Translational Radiotherapy Research Working Group 
(CTRad) formed a Working Group with representatives 
from academia, industry, patient groups and regulatory 
bodies to address this lack of progress and to publish 
recommendations for future research and development. 
This article explains the consensus recommendations of 
the CTRad Working Group, which aim to increase the 
number of novel agents being successfully registered in 
combination with radiotherapy to improve outcomes for 
patients with cancer.
Methods
CTRad was established in 2009 by the UK National 
Cancer Research Institute (NCRI) to focus on clinical 
and translational issues relating to radiotherapy and 
radiobiology. The CTRad Working Group has devel-
oped a portfolio of practice-changing trials and actively 
promotes translation of new discoveries into practice12. 
In September 2014, the CTRad Working Group formed 
at a meeting in London, UK, to identify both barriers 
and solutions to increase the number of clinical  trials 
of drug–radiotherapy combinations and to design 
realistic registration strategies for these combinations. 
The organizing committee approached all pharma-
ceutical and biotechnology companies in a list of con-
tacts collated by the Experimental Cancer Medicine 
Centres (ECMC) and Cancer Research UK (CRUK) 
Combinations Alliance. The Working Group decided 
to provide clear guidelines for researchers and pharma-
ceutical companies working in the field, by publishing a 
Consensus Statement to highlight important opinions 
about the issue of drug–radiotherapy combinations, and 
recommend a particular course of action. Based on the 
summary of the discussions at that meeting, the issues 
were divided into eight topics, with the intention of 
agreeing eight consensus recommendations. It was made 
clear to the Working Group members that the consen-
sus recommendations would be eminence-based, and 
should present a balanced view of the field based on the 
current evidence base.
The follow-up meeting in London in September 2015 
was held with the specific intention of reaching consen-
sus on the eight recommendations from the previous 
year. Invitations were sent to all Working Group mem-
bers who had attended the previous meeting, plus addi-
tional members of the radiotherapy community who 
had shown interest in discussions at CTRad meetings 
subsequent to the previous meeting, as well as additional 
biotechnology and pharmaceutical companies contacted 
via the ECMC/CRUK Combinations Alliance, and 
regu latory contacts at the European Medicines Agency 
(EMA) and Medicines and Health products Regulatory 
Agency (MHRA). The aim was to be as broad and 
inclusive as possible to maximise the impact of the 
 recommendations from the Working Group.
Of the 54 people invited to the meeting in September 
2015, 37 attended and several others contributed with 
comments on the draft consensus statements and fig-
ures, before and after the meeting. All delegates worked 
in small groups to agree on the eight consensus state-
ments: drug–radiotherapy combinations; route to regis-
tration; clinical trial end points; changing the standard 
of care; clinical trial methodology; radiotherapy quality 
assurance; preclinical dataset and target population; and 
patient and consumer involvement to raise awareness 
(BOX 1). All delegates rotated through all eight groups. 
All authors were given the opportunity to comment on 
the manuscript and approve the final version before 
publication. Agreement was reached for the Joint 
Working Group to reconvene in 5–10 years from the 
publication of this article in order to assess progress 
achieved in the  advancement of drug–radiotherapy 
combinations.
Consensus recommendations
Drug–radiotherapy combinations
Principles of radiobiology. Ionizing radiation is most 
often delivered as photons in the X-ray wavelength of 
the electro-magnetic spectrum, but it can also be deliv-
ered as particles in the form of electrons or protons. The 
effect of radiotherapy includes direct damage to DNA 
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in cells, or indirect damage caused by the X-rays col-
liding with molecules within the target, from primary 
and secondary ionisation events. For example, free 
electrons cause damage to molecules other than DNA 
within the cell or in other cells, or can interact with water 
molecules, leading to the generation of hydroxyl radi-
cals or other reactive oxygen species13. Conventional 
radiotherapy is given with curative intent in fractions 
of 1.8–2.0 Gy daily on weekdays up to 35 times. The 
purpose of fractionation is to maximize the killing of 
cancer cells, while minimizing effects on normal tissue 
in and around the target volume. This concept is called 
the Therapeutic Index (FIG. 1). Hypofractionation refers 
to giving a lower number of fractions larger than 2.0 Gy, 
which is more effective per unit dose owing to the cur-
vature of the ionizing radiation dose–response curve, but 
carries greater risk of toxicity to non-malignant tissues. 
Several large-scale clinical trials have found that giving a 
higher (>2.0 Gy) dose of radiotherapy per fraction, and 
a fewer (<35) number of fractions in total, can be as safe 
Box 1 | Consensus statements
1. Drug–radiotherapy combinations
Approximately, 4 out of 10 patients with cancer who are cured by treatment receive radiotherapy. Combining novel drugs 
with radiotherapy has clear potential to significantly improve patient outcomes. When companies are considering 
testing a novel combination for an agent, they should consider drug–radiotherapy combinations as important as  
drug–drug combinations. Collaborative groups involving academia and pharmaceutical companies should prioritise  
the evaluation of appropriate novel drug–radiotherapy combinations early in the clinical development plan of a drug  
to potentially improve response and survival rates. Proposed combinations should have a sound scientific basis in 
radiobiology, immuno-oncology, molecular biology and pharmacology.
2. Route to registration
Currently, there are no published guidelines on how to design studies using novel drug–radiotherapy combinations and 
there is limited guidance on regulatory aspects. In the absence of specific guidance, drug–radiotherapy combinations 
should be viewed as similar in concept to novel drug–drug combinations. There should be a strong scientific rationale 
for the combination based on an understanding of mechanisms of action and a clear line of sight to registration for the 
combination, based on clinical need.
3. Clinical end points
Early communication between regulators and researchers with regard to the most meaningful clinical end point(s) for a 
specific tumour site and patient population will accelerate development of novel combination therapies. Inclusion of 
clinically relevant early and intermediate end points will accelerate clinical development by generating compelling data 
in a timely and cost-effective manner. Regulators should recognize that end points must be pragmatic, relevant to 
patients and applicable in a ‘real world’ setting, and should reflect (i) the important clinical benefits of durable 
locoregional control, and (ii) the balance of effects on tumour control and normal tissue toxicity. Composite or co-primary 
end points might be necessary or advantageous. Secondary end points should usually include assessment of effects on 
normal tissues.
4. Changing the standard of care
The treatment intent and the current standard of care for each disease being treated must be defined by the 
investigators, including any potential variation across countries. Potential changes in the standard of care must be 
predicted by clinical experts if the path to registration is to succeed.
5. Clinical trial methodology
Radiotherapy–combination research requires use of appropriate trial designs and robust statistical strategies based on 
appropriate end points at each stage in the development plan. Studies that take advantage of gaps between planning 
and starting radiotherapy, or between radiotherapy and surgery, are opportunities for early-phase trials and related 
pharmacokinetic, pharmacodynamic and imaging studies.
6. Radiotherapy quality assurance
Quality assured radiotherapy is critical to the success of drug-radiotherapy studies. The components include detailed 
development of the protocol resulting in a transparent description of the chosen technique. Target volume definition 
and the minimization of irradiation to surrounding normal tissues must be described. Pretrial and trial-specific review 
of radiotherapy treatment planning and treatment delivery is essential and should be determined for each study.
7. Preclinical dataset and target population
Similar to novel drug–drug combinations, a standard for a minimum preclinical dataset for justifying early-phase clinical 
development of a new drug–radiotherapy combination does not currently exist. However, it is recommended that the 
dataset should address four considerations: i) demonstrate that the novel drug improves the efficacy of radiotherapy in 
clinically relevant models; ii) define an effective dose schedule; iii) provide an assessment of normal tissue toxicity for the 
drug–radiotherapy combination to identify potential clinical risks; and iv) identify potential responsive patient 
subpopulations and the associated candidate biomarkers.
8. Patient and consumer involvement and raising awareness
Patients and consumer groups should be involved from the concept stage onwards for a clearer understanding of patient 
priorities and what will be considered acceptable by patients who may or may not wish to participate in a clinical trial. 
Efforts to raise public awareness of the efficacy of radiotherapy and drug–radiotherapy combinations should include 
clear statements of the potential benefits of the research to improve cancer treatment.
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as conventional radiotherapy, resulting in a change in 
the standard of care for common cancers, such as breast 
cancer and prostate cancer14,15.
The lethal effects of radiotherapy primarily arise 
from damage to DNA. Radiation-induced DNA lesions 
include base pair damage, single-strand breaks (SSBs) 
and double-strand breaks (DSBs), which are considered 
to be the most lethal. SSBs are more rapidly repaired 
by cells than the DSBs, which are more likely to cause 
mutagenesis or lethality. Approximately, 1 Gy of pho-
ton radiotherapy results in 1 × 105 ionization events per 
cell, producing 1,000–2,000 SSBs and 40 DSBs, with the 
majority of DSB repair occurring within the first 2 h of 
the fraction of radiotherapy16.
Certain biological features of tumours can affect 
outcomes after radiotherapy; for example, the extent 
and degree of hypoxia17, the ability of the surviving 
cells to repopulate within the treatment time (typically 
6–7 weeks for conventionally fractionated radiother-
apy)18, and the intrinsic radioresistance of the tumour 
cells19. In addition, the microenvironment, the immune 
environment, and cellular energetics can also affect 
responses to radiotherapy (FIG. 2), which illustrates the 
multiple biological consequences of radiotherapy.
Novel drug–radiotherapy combinations. Combining 
novel drugs with radiotherapy has clear potential to con-
siderably improve patient outcomes. Moreover, several 
agents in development target each of the radiobiological 
effect categories (FIG. 2). Collaboration between industry 
and academia is essential for progress in this field, and 
should occur as early as possible when a new drug is 
being developed. For industry to invest in new drug–
radiotherapy combinations, a robust scientific basis 
for the combination in preclinical models needs to 
be demonstrated, and a route of registration must be 
defined for each drug–radiotherapy combination in 
terms of patient selection and clinical trial end points.
Proposed drug–radiotherapy combinations should 
have a sound scientific basis with regards to radio-
biology, immuno-oncology, molecular biology and 
pharmacology. Traditionally, strategies for combining 
drugs with radiotherapy have focused either on hypoxia 
modification (BOX 2) or on altering the intrinsic radio-
sensitivity of the irradiated tumour(s) within the tar-
get volume for radiotherapy (BOX 3). Local control of 
the tumour is not the only end point to consider when 
designing a drug–radiotherapy combination strat-
egy (FIG. 2). Radiation-induced bystander effects are 
bio logi cal effects caused in cells that have not been 
directly irradiated20. Such effects include DNA dam-
age, chromo somal instability, mutation, and the induc-
tion of apoptosis21. For example, irradiation of the 
tumour microenvironment (that is, within and around 
the tumour) might be an important determinant of the 
efficacy of radiotherapy22.
A growing interest is placed in combining radio-
therapy with immunotherapy23,24.This particular drug–
radiotherapy combination is emerging as a new field 
of research, termed immuno-radio-oncology (BOX 4). 
Ionising radiation causes immunogenic cell death of 
cancer cells, modulates antigen presentation by cancer 
cells and alters the microenvironment within the irradi-
ated field25–27. Importantly, this approach might pro-
mote enhanced anticancer responses to a systemic drug 
therapy, such as a monoclonal antibody against cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4)28. 
Local radiotherapy can enhance responses to immune- 
modulating agents at sites distant from irradiated areas. 
This phenomenon is known as the abscopal effect, and 
represents an important and exciting development in the 
potential role and scope of radiation therapy, as demon-
strated in an important proof-of-principle clinical trial 
with results published in 2015 (REF. 29). In the next few 
years, improvements in viral and bacterial gene-delivery 
systems30,31 and in oncolytic virotherapy vectors32 might 
result in significant advances in the safety and efficacy of 
gene and viral therapies to target the interaction between 
cancer cells and their microenvironment33.
The route to registration
Existing regulatory guidance on the development of 
chemotherapy and radiotherapy combinations is very 
limited, and early discussion with and scientific advice 
from regulatory agencies is recommended through 
pre-Investigational New Drug (IND) discussions. The 
Committee for Medicinal Products for Human Use 
(CHMP) Guideline on the evaluation of anticancer 
medicinal products in man acknowledges the impor-
tance of combination therapy by combining compounds 
with non-overlapping toxicities and/or mechanisms of 
Figure 1 | Concept of the therapeutic index. A variety 
of strategies have shown promise in ameliorating ionizing 
radiation damage to normal tissues, including protection 
with radical scavengers, stimulating recovery with 
cytokines, modifying the p53 response, reducing the 
negative effects of inflammatory cascades and oxidative 
stress, and the use of stem-cell therapy. Of note, the slopes 
of clinical dose–response curves (the relationship between 
the probability of tumour control and the ionizing radiation 
dose) indicate that increasing the effective ionizing 
radiation dose by just 10% (a dose enhancement factor 
of 1.1) will increase tumour control rates by 5–30%, 
depending on the tumour site and whether control rates 
are already low or high121,122.
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resistance or activity34. The CHMP guideline mentions 
the use of radiotherapy and/or chemotherapy  sensitisers; 
however, given the limited regulatory experi ence of 
such combinations, early interactions with regulators 
need to be undertaken. The FDA published guidance 
on co- development of two or more IND for use in com-
bination35. Although the European Medicines Agency 
CHMP guideline does not address the specific issue of 
the combination of drugs and radiotherapy, it is highly 
relevant in the development of combination therapies in 
general and provides a helpful framework for  discussions 
with the FDA, EMA and other regulators.
Oncology drug development differs from most other 
therapy areas in the early involvement of patients (rather 
than healthy volunteers), usually from first-in-human 
dose-finding study development onwards, and in 
the wide range of academic and collaborative groups 
involved in partnership with the drug developer. This 
scenario should provide early opportunities for consid-
eration of combinations of radiotherapy with chemo-
therapy in patients with cancer. We suggest that, in 
cases with a good biological and therapeutic rationale, 
studies on radiotherapy combinations should be con-
sidered as part of the design of early-phase studies in 
patients (FIG. 3). These protocols might be designed in an 
adaptive manner to support the early initiation of com-
binations once the maximum tolerated dose (MTD) or 
biologically effective dose (BED) for a single agent has 
been established. A clinical development plan for a new 
drug–radiotherapy combination should define ‘go/no go’ 
and potential acceleration criteria (biomarker/efficacy/
toxicity) for each decision point, which can be the move 
from preclinical to phase I, the end of the dose escalation 
part of a phase I study, any cohort expansions in phase I, 
or the move to phase II and phase III trials36.
The early introduction of radiotherapy combina-
tions, either simultaneously or soon after initial market-
ing authorisation, is dependent on the early initiation 
of combination modality studies and a clear pathway 
to registration. Ideally, the initiation of combination 
studies should involve agreement on the tumour site, 
clinical end points to be studied and acceptable clinical 
trial designs from phase I to III. The apparent lack of 
a clear pathway to registration might be a disincentive 
for the developer to undertake early studies. Regulatory 
agencies, however, provide numerous opportunities to 
engage and encourage development of drug–modality 
combinations34,37. For example, EMA Scientific Advice 
can be sought at any stage of development and can pro-
vide the study sponsor with access to a European net-
work of both academic and regulatory experts through 
Scientific Advice Groups (SAG), which include SAG-
Oncology. Such discussions might include the review of 
the biological rationale, clinical study designs or relevant 
clinical study end points. Similar opportunities are pro-
vided by the FDA and other national regulators. Such 
advice is applicable to drug–radiotherapy development 
as well as to new drug–drug combinations.
Given the high number of unmet needs in oncology, 
new agents might possibly be approved under acceler-
ated regulatory procedures, such as the FDA accelerated 
approval scheme, which allows a new drug approval 
owing to intermediate end points — provided subse-
quent confirmatory studies are ongoing to study con-
ventional, long-term end points. The EMA Priority 
Medicines scheme proposed in 2015 will provide 
“enhanced scientific and regulatory support to compa-
nies developing new therapeutic options to patients who 
currently have no treatment options, or a major thera-
peutic advantage over existing treatments” (REF. 38). Early 
engagement with regulators, the academic community, 
patients and stakeholders should occur in the devel-
opment of new therapies to ensure that access to new 
treatments and consequent health improvements are 
achieved in the shortest possible time frame.
The commercial opportunities of novel treatment 
combinations cannot be overlooked (BOX 5). These 
opportunities include repurposing drugs to be used as 
radiosensitisers, for which extensive phase I to IV clinical 
experience of the drug might already exist from their use 
in other indications39. The development route for a new 
drug could include changes to the patent life of candidate 
Figure 2 | Combination strategies to augment the biological ffects of 
radiotherapy. Irradiation of the tumour causes a variety of biological consequences, 
which can be exploited by combining radiotherapy with novel agents that target the 
relevant pathways123. ATR, ataxia telangiectasia and Rad3-related protein; CA9, 
carbonic anhydrase 9; Chk1, checkpoint kinase 1; CTLA-4, cytotoxic T-lymphocyte-
associated protein 4; DDR, DNA damage response; DNA-PK, DNA-dependent protein 
kinase; HIF-1-α, hypoxia-inducible factor 1-alpha; MCT 1, monocarboxylate 
transporter 1; MCT 4, monocarboxylate transporter 4; mTOR, mechanistic target of 
rapamycin ; PARP, poly(ADP-ribose) polymerase; PD-1, programmed cell death protein 1; 
PI3K, phosphoinositide 3-kinase; NF-κB, nuclear factor-kappa-B; UPR, unfolded 
protein response.
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drugs when they are combined with radiotherapy, that is, 
a new indication for the drug. Data exclusivity, market 
protection or patent extensions might be sought on the 
basis of orphan designation or new therapeutic claims 
in many jurisdictions, including the USA and European 
Union (EU)40,41.
Clinical end points
Outside of the palliative setting, the aim of radiotherapy 
treatment is to achieve local and regional tumour control, 
either as the primary treatment modality, or as adjuvant 
or neoadjuvant therapy in combination with surgery. In 
the absence of metastatic disease, loco regional control 
should translate into improvements in disease-free sur-
vival and/or overall survival. In the presence of micro-
metastatic disease, locoregional tumour control might 
still translate into improvements in overall survival, 
symptom-free survival and quality of life (TABLE 1).
The selection of the most meaningful clinical end 
point(s) requires consideration of several factors, which 
include the tumour site, disease stage and target patient 
population. Early or intermediate end points can add 
predictive value, particularly in the context of cancers 
with a better prognosis. The pathological complete 
response (pCR) is the best validated end point for some 
solid cancers in the neoadjuvant setting, such as rectal 
cancer and breast cancer42,43; nevertheless, this surrogate 
end point is not measurable in all disease sites and stand-
ardisation of histopathology procedures requires careful 
quality assurance.
When considering drug-radiotherapy combinations, 
end points that enable evaluation of non- malignant tissue 
toxicity should be included to ensure that improvements 
in tumour control and survival end points do not occur at 
the expense of unacceptable increases in such toxicities. 
Guidance on dose constraints for organs at risk (OARs) 
is based on historical data for radiotherapy alone; inter-
national guidance should be followed in assessing non- 
malignant tissue toxicities for new drug– radiotherapy 
combinations (BOX 6). Whereas the studies from Emami 
et al.44 have historically been used to estimate the dose of 
radiotherapy deliverable to non- malignant tissues when 
radiotherapy is used alone, these conservative estimates 
are not specifically applicable to drug–radiotherapy com-
binations except as a general guide. The need for a sys-
tematic approach to data collection on non- malignant 
tissue toxicities is emphasized by the QUANTEC 
reviews45. For example, in one article from this series, 
the authors emphasize that the biological determinants 
of the risk of non-malignant tissue toxicity vary between 
individuals, and the factors that influence it are specific 
to a given radiation patho genesis46. This is also the case 
for drug–radiotherapy combinations, emphasising the 
need for the collection of accurate data in order to inform 
predictive models that might be developed in the future.
The addition of concomitant cytotoxic chemother-
apy to radical radiotherapy has resulted in increases in 
overall survival and/or disease-free survival in a broad 
range of tumour types (such as cancers of the head and 
neck, lung, cervix, rectum, glioblastoma) and addition of 
molecular targeted agents to radiotherapy has improved 
overall survival and disease-free survival in head and 
neck cancer47,48. Regarding the interests of individuals 
with cancer, regulatory agencies increasingly recognize 
the value of patient-reported outcomes as end points of 
clinical trials49.
Changing the standard of care
For a drug–radiotherapy combination treatment to 
change clinical practice, it is paramount that the com-
bination has demonstrated improved outcomes over 
the existing standard of care. This standard of care can 
vary geographically, and might depend on each coun-
try’s judgement of factors, such as clinical efficacy, cost- 
effectiveness and the balance of toxicities of alternative 
treatment options. Ideally, investigators should ensure 
that the results of the proposed clinical development 
plan are applicable widely, rather than specific to a par-
ticular geographical region; for example, acknowledging 
the widespread use in most countries of platinum-based 
chemotherapy concomitantly with radiotherapy for 
non-small-cell lung cancer (NSCLC) or head and neck 
cancer50. Indeed, one challenge for investigators is that 
clinical trial designs might need to consider how to incor-
porate data on the changing standard of care during the 
study progression.
The key objective of phase I studies of new potential 
anticancer treatments is to determine a recommended 
phase II dose (RP2D) to take forward into further clini-
cal studies. The fundamental assumption that has trad-
itionally underpinned drug development in oncology 
Box 2 | Hypoxia modification
Hypoxic cells are approximately twofold to threefold more radioresistant than 
normoxic cells. Altering oxygenation, for example by ‘normalisation’ of tumour blood 
flow103, would be expected to influence the effectiveness of radiotherapy. Phase II 
and III clinical trials are ongoing in which (chemo)radiation is combined with different 
vasoactive or antiangiogenic drugs. Most of these trials use the two main types of 
antiangiogenic drugs: monoclonal antibodies targeting growth factors or growth factor 
receptors, or small-molecule tyrosine kinase inhibitors. To optimise the ‘normalisation 
window’ for these drugs, non-invasive imaging methods have been developed that can 
monitor blood flow and hypoxia within the target volume (for example, dynamic 
contrast enhanced MRI or positron emission scanning with 18F-misonidazole). Similarly, 
the ability to combine drugs with radiotherapy to improve the therapeutic index will 
depend on the bioavailability of the drug or its active metabolites within areas of poor 
tumour blood flow, for which imaging might assist in assessment.
Box 3 | Altering intrinsic radiosensitisation of irradiated tumours
Intrinsic radiosensitivity is mainly attributable to genetic and epigenetic factors, and to 
the tumour’s capacity to avoid cell death following irradiation. This parameter can be 
studied in vitro, but it can also be modulated in vivo by factors such as oxygenation. 
When used in combination with radiotherapy, traditional radiosensitising drugs 
typically exert their effects by augmenting DNA damage. Significant interest exists in 
developing radiosensitisers that more selectively radiosensitise tumours, but not 
normal, healthy tissues. In particular, signal transduction pathways that regulate 
intrinsic radioresistance, such as the EGFR pathway, have resulted in the efficacy of 
cetuximab when combined with radiotherapy in phase III clinical trials84,104. 
An alternative strategy to widen the therapeutic index for radiotherapy has been to 
radioprotect normal tissues to reduce radiation-induced adverse effects, such as 
xerostomia. Amifostine is an example of this type of drug–radiotherapy combination105.
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is that ‘more is better’; that is, the higher the dose, the 
greater the potential for antitumour activity. This dogma 
has resulted in the RP2D of anticancer treatments usually 
being the MTD — the highest dose of a drug or treatment 
that does not cause unacceptable adverse effects51. This 
concept is not necessarily applicable to molecularly tar-
geted agents, which are associated with different adverse 
effects to cytotoxic chemotherapy drugs, as lower drug 
doses than the MTD can be used to achieve synergy 
for some molecularly targeted agents52. In situations in 
which synergy is expected from the combination of two 
treatment modalities, the mini mal biologically effective 
dose (MBED) of one or both of the treatments might be 
lower than that required for that agent administered as 
monotherapy53,54. Clinically relevant antitumour activity 
(the MBED, or even the maximum therapeutic effect 
(MTE)), might occur at doses significantly lower than the 
MTD55. The ability to use drugs at lower doses in drug– 
radiotherapy combinations than when used as a single 
agent, and possibly for shorter periods of time, can reduce 
drug costs for the combined treatment modality, with 
potentially fewer adverse effects than with the drug alone.
One option to allow delivery of a drug– radiotherapy 
combination in a timely manner is to conduct the 
dose-escalation part of phase I studies of the drug as a 
single agent alongside studies of the drug–radiotherapy 
combination. Data on safety, tolerability and pharmaco-
kinetic (PK) end points from each dose level of the single 
agent study can be incorporated into the parallel study 
of the drug–radiotherapy combination. The choice of 
dose(s) to be explored further with radiotherapy are likely 
to be driven by modelling of the clinical PK data with the 
preclinical efficacy studies to define the expected mini-
mal biologically active dose (MBAD) and, if relevant and 
feasible, tumour tissue sampling of putative biomarkers 
of the MBED (such as serological markers, circulating 
tumour cells or imaging readouts), which can be man-
dated in all patients during the dose escalation part of the 
clinical trial56. These approaches are likely to find the cor-
relation between dose and proof-of-mechanism (PoM) 
or proof-of- principle (PoP) biomarkers, giving a better 
assessment of MBAD57. However, it should be noted that 
the inherent variability of these biomarkers might require 
more than 3–6 patients per cohort for a  meaningful result 
to be obtained.
Phase I oncology studies frequently include small 
expansion cohorts to explore biological activity; the end 
points can be clinical, such as objective response rate 
(ORR), or biomarker-driven, such as paired tumour 
biopsies for PoM or PoP biomarkers. The doses explored 
in these expansion cohorts are usually at, or close to, 
the MTD, but rarely allow determination of MBED. 
A more robust approach is to consider expanding 
cohorts to determine MBAD and test at least one dose 
between MBAD and MTD; such an approach might be 
triggered by significant tumour responses seen in the 
MBAD phase.
Clinical trial methodology
Early-phase trials are required to determine the optimal 
way to give a novel drug in combination with radio-
therapy. Several types of trial design exist and are used 
according to the specific setting and research question 
under evaluation47,58.
Acute toxicity from radiotherapy is not generally a 
good predictor of late toxic effects, with the exception 
of particularly severe or durable acute reactions that can 
have consequential late effects. On account of the risk 
of sub-acute or late toxicities from radiotherapy, clini cal 
trials of drug–radiotherapy combinations might require 
extended follow-up periods, or monitoring of patients 
beyond the routine follow-up period (BOX 7). Extending 
the cohort follow-up period before dose escalation would 
provide a more robust RP2D, and could minimize delay 
by the use of a modification to the continual reassess-
ment method (CRM), the time-to-event (TITE)-CRM59. 
This method incorporates late toxicity events that 
emerge after the typical short-term dose-limiting toxi-
city (DLT) period. The TITE-CRM includes the TITE 
for each patient — the event being a DLT and therefore 
including data from patients whose required follow-up 
period has not yet completed — and also allows the 
potential for patients to be recruited continuously in par-
allel60. Other adaptive study designs might enable more 
robust RP2D decisions than those determined using 
more traditional trial designs, thereby reducing overall 
timelines to reach the primary end point61.
Clinical trial designs that incorporate measures of 
both efficacy and toxicity to identify the correct dose62, 
might offer advantages over traditional dose- escalation 
designs that identify only the MTD. Alternatively, in 
settings where the risk of toxicity to the OAR with a 
drug– radiotherapy combination can vary, alternative 
approaches to dose cohort allocation should be con-
sidered, such as stratification by risk group or isotoxic 
radiotherapy dosing. Isotoxic dosing allows for person-
alised radiotherapy by maximising dose to tumour while 
remaining within pre-defined normal tissue constraints. 
This potentially identifies subgroups of patients more 
likely to respond to therapy and consequently informs 
the design of subsequent phase II and/or phase III  trials. 
Early-phase trials of isotoxic dosing in NSCLC have 
demonstrated promising survival results with limited 
Box 4 | Immuno-radio-oncology
Evidence suggests that radiotherapy can generate clinically significant antitumour 
immunity29,106. Radiotherapy-induced tumour cell death leads to release of ‘danger 
signals’, such as ecto-calreticulin, high mobility group box 1 and damage-associated 
molecular patterns, which recruit antigen-presenting cells that prime tumour 
antigen-specific T-cell responses107. Therapeutic strategies to overcome the body’s 
inhibitory immunosuppressive networks provide an opportunity to generate T-cell 
priming in combination with radiotherapy, inducing antitumour responses outside 
of the radiotherapy field as well as within the target volume (abscopal effect). 
In particular, understanding the role of immune checkpoints in reversing the 
downregulation of antitumour immunity has led to the development of immune- 
stimulating drugs or antagonists of immune suppressor molecules. Both classes of 
drugs are being combined with radiotherapy in clinical trials to broaden the potential 
scope of radiotherapy beyond its traditional use to achieve local control or cure. 
Specifically, radiotherapy is currently evolving from being solely a locoregional 
treatment to becoming a key component of the systemic therapy plan for patients 
with metastatic disease.
C O N S E N S U S  S TAT E M E N T
NATURE REVIEWS | CLINICAL ONCOLOGY  VOLUME 13 | OCTOBER 2016 | 633
©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2016
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
Review of existing
guidelines and
regulatory interactions
Pre-IND meeting
with FDA
End of Phase II meeting with FDA 
and Scientiﬁc Advice EMA
End of Phase I meeting (FDA)
Scientiﬁc Advice EMA or 
National Agencies
Pre-NDA meetings 
CHMP rapporteur assignment 
and presubmission meetings
Nature Reviews | Clinical Oncology
Core programme
Radiotherapy programme
Potential regulatory interactions
Target
selection and
validation
Preclinical
eﬃcacy and
safety
PI
PI
PII PIII
PII/III
Launch
LaunchHypothesisRTMOA
RT-combined
MTD
Preclinical
eﬃcacy and
safety
Monotherapy/
chemotherapy MTD
toxicity63,64. Further trials looking at isotoxic intensity- 
modulated radiation therapy (IMRT) in NSCLC are 
focusing on feasibility, MTD and toxicity65. Research 
into newer techniques such as stereotactic ablative 
radio therapy might benefit from using isotoxic dose 
prescription derived from  experiences of conventionally 
fractionated radiotherapy66.
As more drug–radiotherapy combinations are 
developed, the need to consider more than simply 
drug-dose escalation will arise. Emerging methodolo-
gies developed for drug–drug combinations could be 
applied to drug–radiotherapy combinations for which 
the ‘dose’ of radiotherapy might relate to scheduling 
or sequencing of the drug–radiotherapy combination 
(BOX 8). Multidimensional approaches, such as the pro-
posed Product of Independent beta Probabilities dose 
Escalation (PIPE) design, could be used to identify 
the most promising combinations to take forward to 
phase II trials67. PIPE is an example of a non-parametric 
design for a dual agent clinical trial, in which the model 
parameters are the probabilities of toxicity for each of 
the dose combinations. Some prior knowledge of likely 
toxicities is required to create the model, which can then 
be rapidly updated when toxicity data are obtained in 
the clinical trial. Alternatively, in cases in which multiple 
drugs might be combined with radiotherapy for the first 
time, and recruitment is likely to be steady, cohort alloca-
tion could take the form of a FLIP-FLOP design. In this 
design, dose escalation of each drug occurs in alternate 
cohorts of patients, enabling continued recruitment 
during the toxicity observation period of the  previous 
cohort and maximising patient recruitment rates47.
Scenarios in which a run-in period of single agent 
can precede a drug–radiotherapy combination would 
support efficient evaluation of any changes in the 
pharmaco kinetic and/or pharmacodynamic (PK/PD) 
effects of the drug in the presence of radiotherapy. 
Enrichment trial designs could be employed to further 
develop bio markers or to support appropriate phase III 
trial design68–70. Tissue, biofluid or imaging biomarkers 
have an important role in drug development, particularly 
in preclinical studies and in early-phase clinical trials71. 
Biomarkers can enable the identification of potentially 
successful drugs early on, thus accelerating market 
approval for some therapies. Biomarkers can also ena-
ble the identification of ineffective or toxic compounds 
at the earliest opportunity72. Relatively few combination 
studies, particularly combinations of drug–radiotherapy, 
have incorporated biomarkers to alter decision making 
in early-phase studies, and this represents an important 
area for future research. Earlier consideration of poten-
tial radiotherapy-related biomarkers or biomarkers 
associ ated with mechanisms underpinning a synergistic 
drug–radiotherapy combination might help reduce the 
risk of failure in the phase III setting. ‘Window of oppor-
tunity’ clinical trials permit the development of tissue 
and imaging biomarkers in a short period of time before 
surgery or other definitive treatment73,74. As gains in the 
Figure 3 | Regulatory considerations in trial development of drugs combined with radiotherapy. Early interactions 
with regulatory agencies are recommended because of the limited published regulatory guidance. CHMP, Committee for 
Medicinal Products for Human Use; EMA, European Medicines Agency; IND, investigational new drug; MOA, mechanism 
of action; MTD, maximum tolerated dose; NDA, new drug application; PI/PII/PIII, phase of development of clinical trial;  
RT, radiotherapy.
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therapeutic index can be achieved by improving effi-
cacy or reducing toxicity, phase II designs that support 
 co-primary end points could be useful75.
A key component of successful drug– radiotherapy 
combinations is the use of appropriate, robust end 
points at each phase of assessment. To increase the 
likeli hood of successful phase III trials, decision- making 
in phase II trials should focus on such end points that 
provide reliable information for ‘go/no-go’ decisions. 
Data on late-stage effects should be pooled, which 
will require collaboration between both academic and 
 pharmaceutical partners to share trial data76.
Radiotherapy quality assurance
Adequate quality assurance of treatment delivery 
within clinical trials is critical to the success of drug– 
radiotherapy studies77. The methodology is well- 
established for drugs (manufacture, storage, distribution, 
dosing and compliance) and it should be matched by the 
accuracy of dose delivery from the radiotherapy equip-
ment. Quality assurance of other steps in the process of 
radiotherapy treatment, which is partly individualised 
for each patient based on their anatomy, has been harder 
to achieve than quality assurance of treatment delivery.
As a starting point, the numerous radiotherapy- 
quality assurance (RTQA) procedures and naming con-
ventions used globally have been harmonized in a new 
naming convention to be used in clinical studies incor-
porating radiation therapy78. This overview will facilitate 
intergroup study collaboration, simplifying exchange 
and interpretation of RTQA results (BOX 9). The recom-
mendation is for this process to start early in the devel-
opment of drug–radiotherapy combinations, to ensure 
the radiotherapy component can be adopted widely if 
later phase trials are pursued. Streamlining of the RTQA 
process for these later phase trials, with a centralised cre-
dentialing process, is pursued on a trial-by-trial basis. 
Streamlining prevents clinical sites and central groups 
from being overburdened, and ensures that the level of 
RTQA is consistent with the level of risk and the clinical 
end points of the study.
The electronic data from every patient treated 
within every trial is collated by the UK’s National 
Cancer Research Institute’s Radiotherapy Trials Quality 
Assurance group (NCRI RTTQA) group to allow retro-
spective auditing of protocol adherence. This provides 
an analysable dataset to explore relationships between 
delivered radiation dose and acute or late organ-specific 
toxicity and tumour control. Data from previous trials can 
be used to guide future trials if patients can be  stratified, 
allowing different cohorts to be escalated in parallel.
Preclinical dataset and target population
Appropriate preclinical translational studies are essential 
to provide data that enables the most promising novel 
drug–radiotherapy combinations to be identified and 
progressed. The data should support regulatory approval 
and inform the optimal clinical development programme. 
The preclinical dataset should address four important 
concepts: first, demonstrate that the novel drug improves 
the efficacy of radiotherapy in clinically relevant models 
(both in vitro and in vivo); second, define an effective 
dose schedule; third, provide an assessment of non- 
malignant tissue toxicity for the drug–radiotherapy com-
bination to identify potential clinical risks; and fourth, 
identify potential responsive patient  subpopulations and 
possible candidate biomarkers.
Before designing an early-phase clinical study, investi-
gators must define the proposed treatment in instances of 
unmet need, and select a registerable end point that the 
clinical study will pursue. This will inform on the tissue 
type and end point for the models used in the preclini-
cal phase. For example, if the standard of clinical care is 
cisplatin- based chemoradiotherapy, preclinical model-
ling should ensure that antagonism does not occur 
when the new drug is added to cisplatin-based chemo-
radiation. While in vitro studies should initially be used 
to examine drug–radiotherapy combinations, in vivo 
tumour models are likely to be more informative. There 
has been interest in using mouse models that might be 
more molecularly diverse or possess more complex 
stroma, such as patient-derived xenografts (PDX) or 
genetically engineered mouse models (GEMs)79,80. These 
models have considerable time/resource considerations; 
whether data derived from studies with these models 
would provide substantially more information is unclear. 
However, although cell line-derived tumour xenografts 
remain the principal model for examining efficacy, there 
can be significant value in establishing the effect of an 
intact host immune response on the efficacy of the drug– 
radiotherapy combination and indeed, for combinations of 
immuno therapies (BOX 4) and radiotherapy, syngeneic and 
immuno competent mouse models are essential. Ideally, 
the use of small irradiators in studies involving  animals 
would match the approach to be applied clinically81,82.
As an end point for efficacy studies, tumour cure has 
been considered as the gold standard for assessing the 
impact of drug–radiotherapy combinations. Tumour 
cure is the most comprehensive method, but the gener-
ation of TCD50 values (the dose of radiation required to 
cure 50% of animals) with and without drug is extremely 
labour intensive and impractical for most laboratories. 
In addition, there are examples in which TCD50 data can 
give a distorted view of the value of drug–radiotherapy 
combinations. In some studies, the addition of EGFR 
pathway inhibitors to radiation treatment had no effect 
on TCD50, yet substantial growth delays were observed 
preclinically, and clinical benefit was observed with 
the combination83–85.
Box 5 | Successful drug–radiotherapy combination opportunities
Industry rarely considers drug–radiotherapy combinations if the use of the novel  
agent is limited to 5–7 weeks of a course of radiotherapy. However, this assumption  
is challenged by the concept of ‘adjuvant’ systemic therapy following the  
drug–radiotherapy combination, such as using temozolomide during and after 
radiotherapy to treat glioblastoma multiforme108, by the repurposing of non-cancer 
drugs for use as radiosensitisers39, and by immuno-radio-oncology (BOX 4). Moreover, 
the potential to improve cure rates is cost-effective at a societal level. For example, 
radiotherapy combined with cetuximab versus radiotherapy alone showed dramatic 
improvements in median overall survival and 3-year local control rates for patients  
with advanced-stage head and neck cancer109,110.
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Table 1 | Cancers for which new drug–radiotherapy combinations could be clinically relevant
Cancer type Potential clinical 
impact of 
combination
Examples of potential 
primary, secondary or 
exploratory end points
Justification for choice of potential end points
Breast cancer • Improved OS
• Improved DFS
• Improved QoL
DFS DFS is an accepted surrogate end point in trials of 
adjuvant hormone therapy124
pCR A retrospective analysis of patients with stage 
IV breast cancer indicated that locoregional 
control, mainly with RT alone was associated with 
improved OS43
Cervical 
cancer
Improved OS125 DCE-MRI Improvements in perfusion during radiotherapy 
associated with higher OS126
Locoregional control • Retrospective assessment showed clinical response 
(examination and CT/MRI) was associated with 
5-year DFS and OS following radical CRT127
• Residual disease following RT and surgery was a 
predictive factor for OS128
Squamous cell carcinoma 
antigen (SCC-ag)
Lower levels of SCC-Ag post-treatment predicted 
better 3-year OS129
Prostate 
cancer
• Improved OS
• Improved DFS
• Improved QoL
Serum PSA PSA level following 6 months androgen deprivation 
and RT, and PSA nadir >0.5 ng/ml associated with 
prostate-cancer-specific mortality130
Detection of distant 
metastases
Distant metastasis at 3 years associated with 
prostate-cancer-specific survival at 10 years131
Non-small- 
cell lung 
cancer
Improved OS132 PFS PFS at 2 years correlated with 5-year OS in 
a meta-analysis of patients undergoing RT 
(± chemotherapy) for locally advanced NSCLC133
Locoregional control Strict locoregional control (at least partial response, 
no progression within/adjacent to RT field on CT at 
6 months) associated with OS132 
18F-FDG-PET Higher post-treatment SUV (peak or max) associated 
with worse survival in stage III NSCLC134
Small-cell 
lung cancer
Improved OS PFS PFS at 2 years correlated with 5-year OS in a 
meta-analysis of patients undergoing RT (standard 
versus modified) for locally advanced NSCLC and 
SCLC (10 and 2 trials, respectively)133
CTCs Absolute number of CTCs after 1 cycle of 
chemotherapy predictive for OS in patients 
undergoing chemotherapy or CRT for limited and 
extensive disease135
Bladder 
cancer
• Improved OS136 
• Improved QoL137
pCR pCR associated with improved survival rates138
Patient-reported 
outcomes139
Improved QoL137
Oesophageal 
cancer
Improved OS R0 resection rates Increased R0 resection140 correlated with 5-year 
survival141
pCR pCR associated with improved overall survival in 
patients who received preoperative CRT141
18F-FDG-PET FDG-PET SUV post neoadjuvant CRT correlated 
with 2-year survival142
Rectal cancer • Improved DFS
• Improved QoL
pCR pCR after neoadjuvant CRT associated with high 
5 year DFS and OS in a pooled analysis42
Magnetic Resonance 
Tumour regression grade 
(mrTRG)
mrTRG was independently significant for OS 
and DFS in patients who received neoadjuvant 
long-course CRT143
Anal cancer • Improved OS
• Colostomy-free 
survival144
18F-FDG-PET PFS and OS associated with response on 
18F-FDG-PET145,146
Clinical complete 
response
cCR after RT associated with improved DFS147
Pancreatic 
cancer
Improved PFS Radiological response Local progression at first post-CRT CT imaging was 
a significant prognostic factor for OS148,149
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A growth-delay end point, which evaluates the time 
taken for tumours to reach a defined volume (commonly 
a trebling or quadrupling in volume from treatment 
initiation), is more achievable than tumour cure and 
should be used routinely. After irradiation, tumours 
will generally regrow at the same rate as unirradiated 
tumours. Therefore, by analysing the rate of regrowth 
after treatment, important mechanistic information 
related to drug activity can be obtained — including 
the magnitude and duration of tumour regression in 
relation to pretreatment tumour volume. These experi-
ments should quantify the improvement in the tumour 
response to radiation derived from adding the drug. 
For example, to determine if less radiotherapy can be 
delivered in the presence of the drug to be isoeffective, 
tumour–dose responses for radio therapy alone must 
be established. We also recommend examining a novel 
drug–radiotherapy combination in a minimum of 
two relevant tumour models, and ideally examining a 
 fractionated  radiotherapy schedule.
Efficacy studies should assess drug sequencing in rela-
tion to the timing of radiotherapy treatment. If the drug is 
given before radiotherapy, it might function to condition 
the microenvironment (such as reduce hypoxia), to syn-
chronize cells or to inhibit an immediate response target. 
The drug might need, however, to be present at different 
stages to increase the magnitude of radiation damage (for 
example, a hypoxic cell radiosensitiser). In some cases, 
the drug might need to be present after irradiation to 
inhibit repair or to drive cells down an apoptotic, auto-
phagic or mitotic cell-death pathway. Scheduling experi-
ments will be enhanced by a clear understanding of the 
PK/PD properties of the drug, so that rational dosing can 
be applied during fractionated radiotherapy. Design of 
subsequent clinical work will then need to take account 
of PK/PD observations from first-in-human studies.
A mechanistic rationale will usually indicate why 
tumours should be more affected than non-malignant 
tissue by the combined treatment in the irradiation field. 
Currently, there is no formal prerequisite for combina-
tion toxicology studies to support registration. However, 
given that drug treatment also has the potential to aug-
ment both the early and long-term toxic effects of radio-
therapy, the examination of these effects in preclinical 
models is considered a prudent measure for new mech-
anistic classes of drug and those of the same class with 
differing PK and selectivity profiles.
A preliminary assessment of the skin can be made in 
the proximity of the irradiated tumour86–91. Furthermore, 
acute skin responses can be predictive of late toxicity90,91. 
Box 6 | Non-malignant tissue toxicity
Of all types of medical therapy, radiotherapy service delivery is expected to reach the 
highest standards of quality assurance. Generally recognized guidance on dose 
constraints for organs at risk (OARs) is available:
• QUANTEC45 Emami reports44
• Radiotherapy Oncology Group (RTOG) protocols (https://www.rtog.org/
ClinicalTrials/ProtocolTable.aspx)
End points for non-malignant tissue toxicity can be used in clinical trials, such as:
• cosmesis in breast cancer (FAST trial)111
• proctoscopy at 1 year for rectal toxicity post radiotherapy for prostate cancer112
The individual risk of non-malignant tissue toxicity to radiotherapy treatment can be 
assessed using markers such as serum TGF-β1 levels as a surrogate of fibrosis in breast 
cancer113 and pneumonitis in lung cancer114.
Table 1 (cont.) | Cancers for which new drug–radiotherapy combinations could be clinically relevant
Cancer type Potential clinical 
impact of 
combination
Examples of potential 
primary, secondary or 
exploratory end points
Justification for choice of potential end points
Glioblastoma • Improved OS
• Improved PFS
SPECT imaging Tc-99m (V) DMSA brain SPECT at 4–6 weeks post RT 
was prognostic factor for survival150
T1-weighted 1D size on 
MRI
Linear criteria for measurement of response at 
2 months correlated with PFS and OS151
Head and 
neck cancer
• Improved OS
• Improved DFS
• Improved QoL
PFS 3-year PFS correlated with 5-year OS in 
nasopharyngeal cancer treated with RT152
Locoregional control 
and EFS
Locoregional control and EFS at 2 years was strongly 
correlated with OS at 5 years in a meta-analysis of 
patients treated with CRT153
18F-FDG-PET • Low post-treatment SUV associated with 
better overall survival in a meta-analysis (using 
trial-specified cut-off values)154
• Decrease in SUVmax of ≥50% from baseline to week 
1 or 2 (10 or 20 Gy) of CRT was associated with 
higher 2-year OS155
Examples of some clinical parameters are provided, as they might represent useful primary or secondary end points for certain 
patient subgroups or for important areas of clinical need (for example, likelihood of accelerated approval by regulatory agencies). 
This list of end points is not exhaustive and the end points chosen do not necessarily correlate with overall survival in unselected 
patient groups with the same cancer156. cCR, clinical complete response; CRT, chemoradiation therapy; CTC, circulating tumour 
cells; DCE, dynamic-contrast enhanced; DFS, disease-free survival; DMSA, dimercaptosuccinic acid; EFS, event-free survival; 
LRC, locoregional control; mrTRG, magnetic resonance tumour regression grade; NSCLC; non-small-cell lung cancer; OS, overall 
survival; pCR, pathological complete response; PFS, progression-free survival; PSA; prostate-specific antigen; RT, radiation 
therapy; SCC-ag, squamous cell carcinoma antigen; SCLC, small-cell lung cancer; SPECT, single-photon emission computed 
tomography; SUV, standardized uptake values; SUVmax, maximum SUV. 
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Other non-malignant tissue assays can be prioritised 
based on the tumour site of interest, such as lung pneu-
monitis and fibrosis models for drug–radiotherapy com-
binations used to treat lung cancers, or mucositis models 
in the case of gastrointestinal tumours92–96. These  studies 
must include radiation-only dose responses so that any 
enhancement of toxicity can be interpreted mean-
ingfully, ideally with the same drug dose or radiation 
dose schedules used in complementary efficacy experi-
ments. These studies should then give an indication of 
whether the efficacy of radiotherapy has been prefer-
entially enhanced compared with toxicity, to produce a 
discernable increase in the therapeutic index. Current 
challenges for conducting such studies include a lack of 
standardisation of protocols and limited reporting of 
data. Future studies should aim to benchmark the effects 
of such combinations in model systems to provide guid-
ance on the relevance of findings generated with new 
 drug– radiotherapy combinations.
Novel oncology drugs that enter clinical evalu-
ation are now developed from the outset with a strong 
hypothesis for the subset of cancer patients most likely 
to respond to treatment. Studies will incorporate the use 
of exploratory PD and patient selection biomarkers, the 
latter having the potential to be developed further as a 
companion diagnostic.
A pragmatic approach to patient selection can be to 
examine whether the relevant tumour types also repre-
sent an established setting for the use of radiotherapy 
(TABLE 1). However, a mechanistic basis might exist for 
an enhanced therapeutic effect in the combination of a 
particular signalling inhibitor with radiotherapy, even if 
the inhibitor has little disease modifying activity alone. 
Such an effect can be obtained if the drug treatment 
modulates a key factor that limits the effectiveness of 
radiotherapy (such as DNA repair, cell-cycle phase redis-
tribution, tumour reoxygenation, cellular repopulation, 
and intrinsic radiosensitivity; FIG. 1)97. Furthermore, 
the magnitude of enhancement can be dependent on 
tumour type, and might provide a patient stratification 
hypothesis for the combination. Given the potential for 
mechanistic interactions between novel drugs and radio-
therapy, preclinical studies should be used to carefully 
assess combination regimens, using tumour models that 
are linked to a clinical development strategy. Clinically 
derived ‘signatures’ of prognosis following radical radio-
therapy, on the basis of genomic and microenvironmen-
tal indices, might also be considered for use in patient 
selection once these biomarkers have been validated in 
prospective clinical trials98,99.
Finally, it is important to verify that the PD biomark-
ers being used for drug evaluation are not adversely influ-
enced by radiotherapy treatment. Additional biomarkers 
relevant to radiotherapy (DNA-damage end points, 
tumour vascular perfusion, or tumour hypoxia, among 
others) should be examined, with further elaboration 
using intravital imaging100. Inclusion of these end points 
can provide further mechanistic insight into the effects of 
combination treatment, and might influence the choice 
of methods incorporated into early clinical studies.
Patient and consumer involvement to raise awareness
Within the UK, patients, carers and others affected 
by cancer (consumers) are invited to participate in all 
aspects of the NCRI’s work. All consumers are members 
of the NCRI Consumer Forum, allowing exchange of 
knowledge and expertise in a coordinated way. In 2015, 
the NCRI Consumer Forum stated its guiding prin-
ciple of “working together to build a community with 
the common purpose of providing patient and public 
perspectives throughout the research process, to deliver 
research with better outcomes and experiences for all” 
(REF. 101). The involvement of patients in trial design is 
associated with recognized benefits; patients have better 
outcomes in research-active centres than in other centres, 
and patients involved in research know more about their 
condition than patients without that involvement102. The 
experience and expertise of patients and carers is unique, 
and can inform on trial design. This opportunity enables 
patients to be part of the solution to the problems faced 
by researchers when designing a trial. Radiotherapy and 
drug–radiotherapy combination clinical trials, how-
ever, bring with them added complexity. Patients might 
experi ence increased risk derived from these therapies 
than from standard therapy and, of course, each patient 
and their family will be bringing their own attitude to 
risk, their context and their values into the trial.
Box 7 | Follow-up of late toxicities
On account of the perceived risk of late toxicities, industry sometimes expresses 
concern about long follow-up periods required for clinical trials of drug–radiotherapy 
combinations. During the phase I assessment of anticancer treatments that include 
radiotherapy, it is not uncommon to follow patients for longer than one cycle of drug 
treatment before allowing a dose escalation: the observation can be 56 to 84 days. The 
rationale given for this extended period is to monitor for delayed adverse effects or 
delayed healing after the cessation of radiation treatment. In fact, the late effects of 
exposure to radiotherapy manifest after latent periods of months to years, so could be 
detected by post-trial monitoring of trial participants rather than extending the 
follow-up period for protocol therapy.
Of note, the need for observation beyond the initial ‘acute’ toxicity period is not 
unique to drug–radiotherapy combinations; it is pertinent to all drug trials. Numerous 
small-molecule and large-molecule anticancer treatments are associated with serious 
adverse advents, which have presented later than the end of the first cycle and impact 
safety monitoring of patients who have received the treatment115,116. Some well 
publicised examples include tamoxifen causing endometrial cancer, rofecoxib linked 
to cardiac events, and anthracyclines and trastuzumab leading to cardiotoxicity117–119. 
These examples of non-radiotherapy clinical trials have shown that longer follow-up 
of participants in clinical trials may detect toxicities earlier than phase IV 
post-marketing reporting.
Box 8 | Trial design that could be adapted for drug–radiotherapy combination
The design of a recent clinical study (NCT02264678) enabled increased doses of the ATR 
inhibitor AZD6738 in combination with chemotherapy and/or novel anticancer agent; 
this design could be modified to include a radiotherapy treatment. The study design 
allows changes of study treatment dose and schedule without requiring a protocol 
amendment, enabling rapid response to emerging clinical data. Further treatment 
combinations could be explored by submitting a protocol amendment to open an 
additional module, rather than having to set up a further study, allowing the study to 
respond to changing of standards of care. One such study has two modules: one 
exploring a combination with olaparib, the other a combination with carboplatin, and 
the design has been approved by regulatory authorities in the USA, EU and Korea120.
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The fear of the unknown is present in situations in 
which the patient might already be feeling vulnerable and 
with decreased hope. The experienced utility (what the 
patient is living with) and imagined disutility (what might 
happen) affect patients; mis-imagining the future state has 
a significant bearing on decision-making. Clinicians bring 
what is possible to the discussion; the patient brings their 
preference and what is valuable to them as individuals. To 
overcome potential barriers, patients need transparency. 
They need to know about local control end points and end 
points recognized by regulatory authorities. They need to 
know about de-escalation, organ-sparing, tumour shrink-
age and control, patient-related outcomes and quality of 
life. They need to be involved as early as possible in the 
design of the trial so that there are patient advocates who 
can defend and justify the trial. They require a discourse 
that first presents the benefits, followed by the risks. They 
also need support and coaching to enable them to live 
with uncertainty and accept their situation.
Discussion
Improving long-term control rates and overall survival 
rates from cancer is of significant societal benefit. We have 
illustrated that relatively short treatment periods for drug–
radiotherapy combinations, or relatively modest changes to 
the therapeutic index, have the potential to be cost- effective 
and meaningful for society. Combinations of molecularly 
targeted drugs with radio therapy have generally failed to 
improve overall survival rates for the small number of can-
cers studied with a dual modality approach. Therefore, a 
robust scientific rationale to support new drug–radiother-
apy combinations is of great importance. The preclinical 
package of data required to justify new combinations and 
to reduce risk from an industry perspective has been out-
lined in this docu ment. Collaboration between academia 
and industry, and funding in public–private partnership 
(including academic entrepreneurship) are essential to 
the success of drug–radiotherapy combinations, both in 
preclinical development and in the clinical development 
plan for a new drug. The new research field of immuno- 
radio-oncology is likely to dramatically broaden the scope 
of radiotherapy in the future, beyond its use to achieve 
local control, organ sparing or cure, by the use of radio-
therapy to stimulate responses to systemic therapy. One 
notable example is the abscopal effect.
We have deliberately challenged the view sometimes 
expressed in industry that the route to registration for a 
drug–radiotherapy combination is likely to be long and 
arduous10. Using positive examples, such as the global 
harmonisation of RTQA and the ability to include radio-
therapy in existing clinical trial designs, we have demon-
strated the importance of considering this particular 
combination treatment as early as possible during the 
development plan for a new drug. In addition to the 
well-established role of radiotherapy in treating over half 
of patients diagnosed with cancer, drug–radiotherapy 
combinations offer significant potential for improving 
therapy outcomes. Involving patients early in the pro-
cess, and having honest conversations and explaining the 
benefits followed by the risks are a first step to achieving 
this goal. Based on our collective experience, we encour-
age investigators to follow the guidelines set out in this 
Consensus Statement in order to increase the number 
of novel drugs being successfully registered in combina-
tion with radiotherapy to improve clinical outcomes for 
patients with cancer.
Conclusions
There is an unmet need for rational approaches to drug–
radiotherapy combinations based on molecular under-
standing of radiobiology and our increasing ability to 
translate the most promising results from preclinical 
model systems. The National Cancer Research Institute 
Clinical and Translational Radiotherapy Research 
Working Group (CTRad) formed a Joint Working 
Group with representatives from academia, industry, 
patient groups and regulatory bodies to address the 
recent lack of progress in the field of drug–radiotherapy 
combinations and to publish recommendations for future 
research and development. The Working Group decided 
to divide the courses of action required by investigators 
in this field in to eight topics, and they consequently 
agreed eight eminence-based consensus recommenda-
tions (BOX 1). The aim of this article, and the consensus 
recommendations contained within it, is to increase the 
number of novel agents being successfully registered in 
combination with radiotherapy to improve outcomes 
for patients with cancer. The Joint Working Group will 
reconvene in 5–10 years from publication of this article 
in order to assess progress achieved in the advancement 
of drug–radiotherapy combinations.
Box 9 | Approaches to radiotherapy trials quality assurance
The UK’s National Cancer Research Institute’s Radiotherapy Trials Quality Assurance group 
(NCRI RTTQA; http://www.rttrialsqa.org.uk/rttqa/) is one of several international groups 
leading this field. The NCRI RTTQA has a risk-adapted approach to RTQA, with 
individualized real-time case reviews of all patients treated within trials of new radiotherapy 
techniques or novel drug-radiation combinations mandated. NCRI RTTQA activity includes:
• Review trial submission before funding, linking investigators to previous and/or ongoing 
investigators in the same disease to support streamlining and consistency
• Review detailed radiotherapy protocol, involving external experts and organization of 
protocol development meetings if needed
• Development, circulation, assessment and feedback of pre-trial benchmark outlining 
and planning cases
• Development of outlines and plans of risk-adapted on-trial clinical case reviews
• Real-time review of variations from protocol
• Site visits to ensure accuracy of dose delivery and image guidance procedures for novel 
radiotherapy techniques
• Collation of electronic radiation dosimetry data (dose cubes) for subsequent dose 
volume analysis
The international requirement for harmonisation of radiotherapy quality assurance 
(RTQA) within clinical studies led to the formation of the Global Clinical Trials Quality 
Assurance of Radiation Therapy Harmonisation Group (http://rtqaharmonisation.org/) 
in 2010, with the following goals78:
• Collate, homogenise and distribute information regarding the RTQA standards of the 
clinical trial groups
• Provide a platform for prospective discussions on new RTQA procedures, software tools, 
guidelines and policies of trial groups
• Provide a framework to endorse existing and future RTQA procedures and guidelines 
across various trial groups
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